Particularly, it could lead to identify primary or acquired resistance mechanisms to platinum-based chemotherapy or PARP inhibitors, such as accumulation of somatic mutations restoring the HR system on cancer cells and to evaluate allelic specific loss of heterozygosity [9,16,39]. This evidence concerns the gene PARP1 and cancer.